Details

Autor(en) / Beteiligte

• De Liso, P
• Vigevano, F
• Specchio, N
• De Palma, L
• Bonanni, P
• Osanni, E
• Coppola, G
• Parisi, P
• Grosso, S
• Verrotti, A
• Spalice, A
• Nicita, F
• Zamponi, N
• Siliquini, S
• Giordano, L
• Martelli, P
• Guerrini, R
• Rosati, A
• Ilvento, L
• Belcastro, V
• Striano, P
• Vari, M.S
• Capovilla, G
• Beccari, F
• Bruni, O
• Luchetti, A
• Gobbi, G
• Russo, A
• Pruna, D
• Tozzi, A.E
• Cusmai, R

Titel

Effectiveness and tolerability of Perampanel in children and adolescents with refractory epilepsies − an Italian observational multicenter study

Ist Teil von

• Epilepsy research, 2016-11, Vol.127, p.93-100

Ort / Verlag

Netherlands: Elsevier B.V

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• Highlights • In this retrospective observational study carried out in Italy, 62 patients with refractory epilepsy of various origins (8 patients aged < 12 years) started treatment with perampanel as add-on therapy with exclusion of primary idiopathic generalized epilepsy. • At a median follow-up of 6.6 months, treatment with perampanel was associated with an overall response rate (reduction in seizures frequency ≥ 50% vs. baseline) in half of patients with 5% of patients becoming seizure free. The overall number of seizures significantly decreased from baseline to follow-up. • Adverse events (mainly consisting of behavioral disturbances, dizziness and sedation) occurred in 19 patients (30.6%). • Four patients (9.7%) stopped medication beacause of lack of efficacy and 10 for adverse events, 6 of them for aggravation of seizures. • These preliminary data indicate that perampanel was effective in children and adolescents with refractory epilepsies, and exhibited an acceptable safety profile.